BioPharmSignal logoBioPharmSignal

Biotech News

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Beam Therapeutics (BEAM)Beam TherapeuticsCommercial

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr.

Related news

BEAMBeam Therapeutics2026-01-11 22:00 EST

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

BEAMBeam Therapeutics2026-07-23 11:00 EST

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

View all latest news

Beam Therapeutics

Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is...

Recent company news

BEAMBeam Therapeutics2026-09-08 10:00 EST

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

BEAMBeam Therapeutics2026-09-01 11:00 EST

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

BEAMBeam Therapeutics2026-08-31 11:00 EST

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

BEAMBeam Therapeutics2026-08-04 11:00 EST

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

BEAMBeam Therapeutics2026-07-23 11:00 EST

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Stock data

Close
24.67 USD
Market cap
2.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States